Company facts
- Headquarters
- Antwerpen
- Most recent report
- 6-K, filed Oct 13, 2026
- Filings on record
- 47 filings
- On EDGAR
- CIK 2020932
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Emerging growth company
Financials 8 of 12
- 6-K Report a foreign issuer made public elsewhere Oct 13, 2026
- 6-K Report a foreign issuer made public elsewhere Oct 1, 2026
- 6-K Report a foreign issuer made public elsewhere Sep 14, 2026
- 6-K Report a foreign issuer made public elsewhere Sep 11, 2026
- 6-K Report a foreign issuer made public elsewhere Aug 10, 2026
- 6-K Report a foreign issuer made public elsewhere Aug 6, 2026
- 6-K Report a foreign issuer made public elsewhere Jun 23, 2026
- 6-K Report a foreign issuer made public elsewhere May 27, 2026
Prospectuses and Registrations 3
Ownership 8 of 25
- 4 Insider reported a trade Oct 9, 2026
- 4 Insider reported a trade Oct 7, 2026
- 4 Insider reported a trade Oct 7, 2026
- 4 Insider reported a trade Oct 7, 2026
- 4 Insider reported a trade Sep 15, 2026
- 4 Insider reported a trade Sep 15, 2026
- 3 Insider reported their initial holding Sep 15, 2026
- 3 Insider reported their initial holding Sep 15, 2026
Other 7
- CERT Exchange certified a listing Feb 5, 2026
- 8-A12B Registration of a security for exchange listing Feb 3, 2026
- EFFECT Notice that a registration became effective Jan 30, 2026
- F-1/A Registration statement, foreign issuer, amended Jan 29, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Dec 17, 2025
- DRS/A Draft registration statement, submitted confidentially, amended Oct 28, 2025
- DRS Draft registration statement, submitted confidentially Jun 20, 2024
Everything here comes from AgomAb Therapeutics NV's own filings on SEC EDGAR. The filing list is rechecked every hour.